Suppr超能文献

I 型脊肌萎缩症患者接受疾病修正治疗后管饲的预后因素:一项队列研究。

Prognostic factors for tube feeding in type I SMA patients treated with disease-modifying therapies: a cohort study.

机构信息

Pediatric Neurology, Università Cattolica del Sacro Cuore, Rome, Italy.

Centro Clinico Nemo, Neuropsichiatria Infantile, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.

出版信息

Eur J Pediatr. 2024 Nov;183(11):4735-4745. doi: 10.1007/s00431-024-05735-9. Epub 2024 Aug 29.

Abstract

The aim of this study was to assess the need for tube feeding in a cohort of treated infants with type I SMA and to identify predictive factors. All patients were classified at baseline, when treatment started, and at follow-up according to their functional level and the need for tube feeding. Fisher's exact test was used to examine the associations between the outcome at the last follow-up and SMA type, SMN2 copy number, and baseline nutritional status. ANOVA was performed to compare CHOP INTEND scores and age at treatment initiation with outcomes. The cohort includes 75 type I SMA infants treated between 0.1 and 5 years of age. At the last follow-up, 34 had no need for tube feeding, 9 had tube feeding but were also able to be fed by mouth, and 32 had tube feeding and were unable to be fed by mouth. Thirty of the 41 infants with tube feeding at follow-up already had feeding difficulties when treatment was started. The need for tube feeding at follow-up was associated with the level of feeding involvement at baseline and with CHOP INTEND scores [p < 0.001] but not with SMN2 copy number, SMA type 1 subtypes or age at treatment. The results of this study suggest that the need for tube feeding is not frequent in treated infants with type I SMA and, when occurring, can be predicted by the level of feeding involvement and low CHOP INTEND scores at baseline. What is Known: • The advent of disease-modifying therapies is increasingly changing the approach to swallowing and nutritional management in type I SMA. • Clinical trials and real-world data using all three disease-modifying therapies report a rather wide variability of feeding outcome and need for tube feeding that is often related to different cohorts that makes comparison between studies very difficult. What is New: • The real-world findings of this study, including all the children treated since treatments became available, confirmed that the need for tube feeding is not an invariable finding. • The level of feeding involvement at baseline appears to be a reliable prognostic indicator of bulbar outcome. • The results highlight the need for interventional studies with structured Speech and Language Therapist protocols that will help to better understand the extent to which bulbar function can be maintained or regained even in children requiring tube feeding.

摘要

本研究旨在评估 I 型 SMA 治疗患儿群体中管饲的需求,并确定预测因素。所有患者均在基线、治疗开始时和随访时根据其功能水平和管饲需求进行分类。Fisher 确切检验用于检验最后一次随访结果与 SMA 类型、SMN2 拷贝数和基线营养状况之间的关联。方差分析用于比较 CHOP INTEND 评分和治疗起始年龄与结局的关系。该队列包括 75 名 0.1 至 5 岁接受治疗的 I 型 SMA 患儿。最后一次随访时,34 名患儿无需管饲,9 名患儿需要管饲但仍可经口喂养,32 名患儿需要管饲且无法经口喂养。随访时需要管饲的 41 名患儿中有 30 名在开始治疗时已经存在喂养困难。随访时需要管饲与基线时喂养受累程度和 CHOP INTEND 评分相关(p<0.001),但与 SMN2 拷贝数、SMA 1 型亚型或治疗时年龄无关。本研究结果表明,I 型 SMA 治疗患儿中管饲的需求并不常见,而且当发生时,可以通过基线时的喂养受累程度和低 CHOP INTEND 评分来预测。已知:• 疾病修饰疗法的出现正在逐渐改变 I 型 SMA 的吞咽和营养管理方法。• 使用三种疾病修饰疗法的临床试验和真实世界数据报告了相当广泛的喂养结局和管饲需求的变异性,这往往与不同的队列有关,使得研究之间的比较非常困难。新发现:• 本研究的真实世界发现,包括自治疗可用以来治疗的所有儿童,证实管饲的需求并非不变的发现。• 基线时的喂养受累程度似乎是球部结局的可靠预后指标。• 这些结果强调了需要进行干预性研究,采用结构化的言语治疗师方案,以帮助更好地了解即使需要管饲的患儿,球部功能在多大程度上可以得到维持或恢复。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验